Asphalion’s Board of Directors is pleased to announce the appointment of Christopher Mann as new Scientific and Regulatory Affairs Director.
Christopher has a PhD in Biochemistry (Molecular biology) in gene therapy for muscular dystrophy.
He has been an academic researcher in gene therapy, muscle regeneration and muscular dystrophy as well as diabetes for 15 year and has published numerous original research papers and review articles in peer reviewed journals.
He is also an expert in medical and scientific writing for Advanced Therapy Medicinal Products (ATMPs), Biosimilars, Biological, Biotechnological and other Innovative products, and has also additional expertise in pediatric development (EU and FDA), Scientific Advice/ Pre-IND meetings and Centralized Procedures. He has also been work package leader for several research consortia, including projects with ATMPs.
Our team possesses strong technical knowledge and long experience in the industry to help our clients in any challenge. We are very confident that with Christopher Mann’s leadership we will deliver great value, support and innovation to our customers. The growth of our team is intrinsically linked to that of our clients: We aim to keep growing together and envision a great future ahead.
We would like to thank Christopher for embracing this challenge.
Asphalion is an international Scientific and Regulatory Affairs consultancy company with offices in Barcelona, Madrid, Munich and London. Founded in 2000, it has consistently grown, and now employs more than 100 team members from 12 different nationalities with backgrounds in Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology and Medicine. Asphalion collaborates with Pharmaceutical, Biotechnological and Medical Technology organizations facilitating product development and regulatory affairs solutions for their projects.